Ticker Details
Viking Therapeutics, Inc. Viking Therapeutics Inc is a clinical-stage biopharmaceutical company. The company develops therapies for metabolic and endocrine disorders. It includes portfolio of five drug candidates in clinical trials or preclinical studies.
IPO Date:	April 29, 2015
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$3.59B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.46 | 3.33%
Avg Daily Range (30 D):	$1.02 | 3.27%
Avg Daily Range (90 D):	$0.97 | 2.84%

Institutional Daily Volume
Avg Daily Volume:	1.87M
Avg Daily Volume (30 D):	3.1M
Avg Daily Volume (90 D):	3.18M

Trade Size
Avg Trade Size (Sh.):	114
Avg Trade Size (Sh.) (30 D):	82
Avg Trade Size (Sh.) (90 D):	79

Institutional Trades
Total Institutional Trades:	5,020
Avg Institutional Trade:	$2.74M
Avg Institutional Trade (30 D):	$1.98M
Avg Institutional Trade (90 D):	$2.13M
Avg Institutional Trade Volume:	.1M
Avg Institutional Trades (Per Day):	3

Market Closing Trades
Avg Closing Trade:	$6.38M
Avg Closing Trade (30 D):	$6.41M
Avg Closing Trade (90 D):	$7.46M
Avg Closing Volume:	248.51K

News

Feb 24, 2026 @ 1:30 AM Got $5,000? Viking Therapeutics Might Be a WeightÃ... Source: Prosper Junior Bakiny

Feb 23, 2026 @ 7:29 PM Viking Therapeutics Stock Gains Amid Obesity Drug ... Source: Vandana Singh

Feb 23, 2026 @ 10:10 AM 3 Reasons Viking Therapeutics Stock Could 10X if I... Source: Adria Cimino

Feb 17, 2026 @ 1:15 PM 2026 Could Be a Big Year for Viking Therapeutics. ... Source: Adria Cimino

Feb 13, 2026 @ 4:26 PM Accessible Health Platforms Gain Scale Across $6T ... Source: Prnewswire

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$-3.19	$-1.39	$-3.19
Diluted EPS	$-3.19	$-1.39	$-3.19
Revenue	$M	$M	$M
Gross Profit
Net Income / Loss	$-359.64M	$-157.66M	$-359.64M
Operating Income / Loss	$-393.34M	$-164.74M	$-393.34M
Cost of Revenue
Net Cash Flow	$139.14M	$65.43M	$139.14M
PE Ratio